NGL Fine-Chem Limited - Asset Resilience Ratio
NGL Fine-Chem Limited (NGLFINE) has an Asset Resilience Ratio of 7.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NGL Fine-Chem Limited current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2026)
This chart shows how NGL Fine-Chem Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NGL Fine-Chem Limited total assets.
Liquid Assets Composition Over Time
This chart breaks down NGL Fine-Chem Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read NGL Fine-Chem Limited debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs391.88 Million | 7.18% |
| Total Liquid Assets | Rs391.88 Million | 7.18% |
Asset Resilience Insights
- Limited Liquidity: NGL Fine-Chem Limited maintains only 7.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NGL Fine-Chem Limited Industry Peers by Asset Resilience Ratio
Compare NGL Fine-Chem Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for NGL Fine-Chem Limited (2013–2026)
The table below shows the annual Asset Resilience Ratio data for NGL Fine-Chem Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 7.18% | Rs391.88 Million ≈ $4.24 Million |
Rs5.45 Billion ≈ $58.99 Million |
-6.58pp |
| 2025-03-31 | 13.77% | Rs596.64 Million ≈ $6.45 Million |
Rs4.33 Billion ≈ $46.87 Million |
-1.68pp |
| 2024-03-31 | 15.45% | Rs549.19 Million ≈ $5.94 Million |
Rs3.56 Billion ≈ $38.45 Million |
-0.11pp |
| 2023-03-31 | 15.56% | Rs446.74 Million ≈ $4.83 Million |
Rs2.87 Billion ≈ $31.05 Million |
+5.12pp |
| 2022-03-31 | 10.44% | Rs289.05 Million ≈ $3.13 Million |
Rs2.77 Billion ≈ $29.95 Million |
-4.84pp |
| 2021-03-31 | 15.28% | Rs317.47 Million ≈ $3.43 Million |
Rs2.08 Billion ≈ $22.47 Million |
+6.07pp |
| 2020-03-31 | 9.21% | Rs141.50 Million ≈ $1.53 Million |
Rs1.54 Billion ≈ $16.61 Million |
+0.48pp |
| 2019-03-31 | 8.74% | Rs124.21 Million ≈ $1.34 Million |
Rs1.42 Billion ≈ $15.38 Million |
+1.34pp |
| 2018-03-31 | 7.40% | Rs95.61 Million ≈ $1.03 Million |
Rs1.29 Billion ≈ $13.98 Million |
+2.41pp |
| 2017-03-31 | 4.98% | Rs50.44 Million ≈ $545.44K |
Rs1.01 Billion ≈ $10.95 Million |
+0.97pp |
| 2016-03-31 | 4.01% | Rs31.10 Million ≈ $336.33K |
Rs775.06 Million ≈ $8.38 Million |
+0.89pp |
| 2015-03-31 | 3.12% | Rs20.74 Million ≈ $224.29K |
Rs665.17 Million ≈ $7.19 Million |
+2.38pp |
| 2014-03-31 | 0.74% | Rs4.15 Million ≈ $44.86K |
Rs558.46 Million ≈ $6.04 Million |
+0.65pp |
| 2013-03-31 | 0.09% | Rs424.10K ≈ $4.59K |
Rs473.96 Million ≈ $5.13 Million |
-- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more